HC Wainwright Reiterates $15.00 Price Target for Corium International, Inc. (CORI)

HC Wainwright set a $15.00 price target on Corium International, Inc. (NASDAQ:CORI) in a report issued on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

CORI has been the subject of several other research reports. BidaskClub lowered shares of Corium International from a buy rating to a hold rating in a report on Thursday, August 3rd. ValuEngine lowered shares of Corium International from a hold rating to a sell rating in a report on Thursday, August 24th. Jefferies Group LLC set a $10.00 price target on shares of Corium International and gave the company a buy rating in a report on Sunday, October 29th. Zacks Investment Research lowered shares of Corium International from a buy rating to a sell rating in a report on Tuesday, October 10th. Finally, Needham & Company LLC reissued a buy rating and issued a $13.00 price target on shares of Corium International in a report on Sunday, September 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. Corium International currently has a consensus rating of Buy and an average target price of $13.00.

Corium International (NASDAQ CORI) opened at $11.43 on Friday. Corium International has a fifty-two week low of $2.67 and a fifty-two week high of $11.65. The company has a current ratio of 7.04, a quick ratio of 6.80 and a debt-to-equity ratio of 1.89.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://ledgergazette.com/2017/11/20/hc-wainwright-reiterates-15-00-price-target-for-corium-international-inc-cori-5.html.

In related news, major shareholder Healthcare Master Fun Broadfin sold 150,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $11.05, for a total value of $1,657,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Parminder Singh sold 30,415 shares of the company’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $7.59, for a total transaction of $230,849.85. Following the completion of the transaction, the insider now directly owns 30,762 shares of the company’s stock, valued at $233,483.58. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 898,515 shares of company stock valued at $9,769,631. Company insiders own 45.70% of the company’s stock.

Several institutional investors have recently bought and sold shares of CORI. Bank of New York Mellon Corp boosted its stake in shares of Corium International by 118.1% during the 1st quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 13,683 shares during the last quarter. Teachers Advisors LLC acquired a new position in shares of Corium International during the 2nd quarter worth about $272,000. TIAA CREF Investment Management LLC acquired a new position in shares of Corium International during the 2nd quarter worth about $411,000. New York State Common Retirement Fund acquired a new position in shares of Corium International during the 2nd quarter worth about $158,000. Finally, EAM Investors LLC acquired a new position in shares of Corium International during the 2nd quarter worth about $563,000. Institutional investors own 89.96% of the company’s stock.

Corium International Company Profile

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply